{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:39:44Z","timestamp":1789479584817,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.06.002","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T07:09:26Z","timestamp":1751008166000},"page":"1150-1164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies"],"prefix":"10.1016","volume":"8","author":[{"given":"Michaela","family":"Lunan-Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit D.","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Thi","family":"Nhan Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Quintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.06.002_b0005","unstructured":"IARC. Estimated number of new cases in 2020, world, both sexes, all ages (excl. NMSC). International Agency for Research on Cancer; 2020."},{"key":"10.1016\/j.euo.2025.06.002_b0010","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration\u2010resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euo.2025.06.002_b0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajur.2018.11.005","article-title":"Metastatic prostate cancer remains incurable, why?","volume":"6","author":"Dong","year":"2019","journal-title":"Asian J Urol"},{"key":"10.1016\/j.euo.2025.06.002_b0020","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US Prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.euo.2025.06.002_b0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/cancers15020461","article-title":"Metastatic prostate cancer\u2014a review of current treatment options and promising new approaches","volume":"15","author":"Posdzich","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2025.06.002_b0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.002_b0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41391-017-0020-y","article-title":"Current approaches to incorporation of radium-223 in clinical practice","volume":"21","author":"Parker","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.06.002_b0040","doi-asserted-by":"crossref","unstructured":"McManus HD, Dorff T, Morgans AK, Sartor O, Shore N, Armstrong AJ. Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. Prostate Cancer Prostatic Dis. In press. https:\/\/doi.org\/10.1038\/s41391-024-00906-z.","DOI":"10.1038\/s41391-024-00906-z"},{"key":"10.1016\/j.euo.2025.06.002_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102864","article-title":"Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: a review","volume":"146","author":"Cursano","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.euo.2025.06.002_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.1016\/j.euo.2025.06.002_b0055","unstructured":"Higgins JT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane; 2023."},{"key":"10.1016\/j.euo.2025.06.002_b0060","unstructured":"NICE. NICE process and methods [PMG20]. Appendix H: appraisal checklists, evidence tables, GRADE and economic profiles. NICE; 2023."},{"key":"10.1016\/j.euo.2025.06.002_b0065","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/iju.15008","article-title":"Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: a large database study","volume":"29","author":"Kawahara","year":"2022","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2025.06.002_b0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00259-015-3185-4","article-title":"Factors affecting 223 Ra therapy: clinical experience after 532 cycles from a single institution","volume":"43","author":"Etchebehere","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2025.06.002_b0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/fon-2021-0886","article-title":"Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC","volume":"18","author":"Sartor","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0080","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.21873\/anticanres.12873","article-title":"Single-centre experience of use of radium 223 with clinical outcomes based on number of cycles and bone marrow toxicity","volume":"38","author":"Dadhania","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euo.2025.06.002_b0085","doi-asserted-by":"crossref","first-page":"107.e1","DOI":"10.1016\/j.clgc.2022.09.002","article-title":"Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden","volume":"21","author":"Stattin","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.06.002_b0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.clgc.2022.04.015","article-title":"Lower fracture rates in patients treated with radium-223, abiraterone or enzalutamide, when given concurrently with bone health agents: a real-world analysis","volume":"20","author":"Trieu","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.06.002_b0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/JCO.2024.42.4_suppl.79","article-title":"Real-world utilization patterns of radium-223 in metastatic prostate cancer in the United States: an administrative claims database study","volume":"42","author":"Raval","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0100","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1002\/cam4.5262","article-title":"Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: a real-world evidence multicenter study","volume":"12","author":"Hyv\u00e4kk\u00e4","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.euo.2025.06.002_b0105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41391-020-00271-7","article-title":"Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center","volume":"24","author":"McKay","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.06.002_b0110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/pros.23286","article-title":"Clinical correlates of benefit from radium-223 therapy in metastatic castration resistant prostate cancer","volume":"77","author":"Alva","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.06.002_b0115","doi-asserted-by":"crossref","first-page":"9307","DOI":"10.2147\/CMAR.S213051","article-title":"Population-based analysis of the use of radium-223 for bone-metastatic castration-resistant prostate cancer in Ontario, and of factors associated with treatment completion and outcome","volume":"11","author":"Cheng","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.euo.2025.06.002_b0120","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/j.clgc.2016.08.015","article-title":"Radium-223 use in clinical practice and variables associated with completion of therapy","volume":"15","author":"McKay","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.06.002_b0125","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2967\/jnumed.123.265557","article-title":"Pain outcomes in patients with metastatic castration-resistant prostate cancer treated with 223Ra: PARABO, a prospective, noninterventional study","volume":"64","author":"Palmedo","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2025.06.002_b0130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clon.2018.06.004","article-title":"Real-world outcomes and factors predicting survival and completion of radium 223 in metastatic castrate-resistant prostate cancer","volume":"30","author":"Parikh","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0135","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1007\/s00345-021-03639-z","article-title":"A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer","volume":"39","author":"Miyoshi","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.06.002_b0140","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2217\/fon-2020-0039","article-title":"Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer","volume":"16","author":"Kuppen","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5489\/cuaj.7591","article-title":"A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer","volume":"16","author":"Charrois-Durand","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euo.2025.06.002_b0150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/wjnm.WJNM_74_20","article-title":"Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases","volume":"20","author":"Buscombe","year":"2021","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.euo.2025.06.002_b0155","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41391-021-00488-0","article-title":"Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)","volume":"25","author":"George","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.06.002_b0160","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.clon.2020.05.002","article-title":"Optimising radium 223 therapy for metastatic castration-resistant prostate cancer\u20145-year real-world outcome: focusing on treatment sequence and quality of life","volume":"32","author":"Jiang","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0165","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1016\/j.clgc.2018.10.013","article-title":"Results from a large, multicenter, retrospective analysis on radium223 use in metastatic castration-resistant prostate cancer (mCRPC) in the Triveneto Italian region","volume":"17","author":"Maruzzo","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.06.002_b0170","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1002\/cam4.4125","article-title":"Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with radium-223","volume":"10","author":"Al-Ezzi","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.euo.2025.06.002_b0175","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41391-020-0236-0","article-title":"Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone\/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer","volume":"23","author":"Shore","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.06.002_b0180","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1007\/s00259-021-05283-6","article-title":"Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223","volume":"48","author":"van der Doelen","year":"2021","journal-title":"Eur J Nuclear Med Mol Imaging"},{"key":"10.1016\/j.euo.2025.06.002_b0185","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41391-022-00569-8","article-title":"Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy","volume":"26","author":"van der Doelen","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.06.002_b0190","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pros.24115","article-title":"Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population","volume":"81","author":"Zhao","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.06.002_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101993","article-title":"Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer","volume":"60","author":"Higano","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.euo.2025.06.002_b0200","doi-asserted-by":"crossref","first-page":"S984","DOI":"10.1016\/j.annonc.2023.09.2764","article-title":"1816P Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study","volume":"34","author":"Tombal","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0205","volume":"35","author":"Gillessen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0210","doi-asserted-by":"crossref","first-page":"S1259","DOI":"10.1016\/j.annonc.2024.08.2314","article-title":"LBA71 Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)","volume":"35","author":"Conteduca","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0215","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/ijc.32851","article-title":"A prospective observational registry evaluating clinical outcomes of radium-223 treatment in a nonstudy population","volume":"147","author":"Badrising","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2025.06.002_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1526","article-title":"1394P Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study","volume":"33","author":"O'Sullivan","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0225","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euo.2023.09.015","article-title":"Prospective assessment of bone metabolism biomarkers and survival in metastatic castration-resistant prostate cancer patients treated with radium-223: the PRORADIUM study","volume":"7","author":"Romero-Laorden","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0230","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0235","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","article-title":"Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333\/PEACE-3 trial comparing radium-223 combined with enzalutamide versus enzalutamide alone: a safety analysis","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.002_b0240","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0245","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.002_b0250","article-title":"Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer","volume":"9","author":"O'Sullivan","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.euo.2025.06.002_b0255","unstructured":"European Medicines Agency. EMA restricts use of prostate cancer medicine Xofigo. EMA; 2018."},{"key":"10.1016\/j.euo.2025.06.002_b0260","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3390\/cancers14071744","article-title":"Prognostic value of the BIO-Ra score in metastatic castration-resistant prostate cancer patients treated with radium-223 after the European Medicines Agency restricted use: secondary investigations of the multicentric BIO-Ra study","volume":"14","author":"Bauckneht","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2025.06.002_b0265","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/pros.24143","article-title":"Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings","volume":"81","author":"Sartor","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.06.002_b0270","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/pros.24375","article-title":"The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases","volume":"82","author":"Liu","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.06.002_b0275","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s00259-018-4051-y","article-title":"Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer","volume":"45","author":"Castello","year":"2018","journal-title":"Eur J Nuclear Med Mol Imaging"},{"key":"10.1016\/j.euo.2025.06.002_b0280","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/1874471011666180629145030","article-title":"Final outcome of223Ra-therapy and the role of18F-fluoride-PET in response evaluation in metastatic castration-resistant prostate cancer\u2014a single institution experience","volume":"11","author":"Kairemo","year":"2018","journal-title":"Curr Radiopharm"},{"key":"10.1016\/j.euo.2025.06.002_b0285","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2023.41.6_suppl.203","article-title":"Circulating tumor DNA and homologous recombination deficiency in bone-predominant mCRPC prior to radium-223 therapy","volume":"41","author":"Yang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0290","first-page":"310","article-title":"Prognostic biomarkers in the use of radium-223 in patients with metastatic castration-resistant prostate cancer","volume":"42","author":"Vidal","year":"2023","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"10.1016\/j.euo.2025.06.002_b0295","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/pcan.2017.6","article-title":"Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases\u2014analysis of an international multicenter database","volume":"20","author":"Keizman","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.06.002_b0300","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/fon-2020-0391","article-title":"Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients","volume":"17","author":"Caffo","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0305","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-021-05550-6","article-title":"The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)","volume":"49","author":"Bauckneht","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2025.06.002_b0310","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40520-020-01573-5","article-title":"A national multicenter study on overall survival in elderly metastatic castrate-resistant prostate cancer patients treated with radium-223","volume":"33","author":"Frantellizzi","year":"2021","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.euo.2025.06.002_b0315","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/biomedicines11041103","article-title":"The DASciS software for BSI calculation as a valuable prognostic tool in mCRPC treated with 223RaCl2: a multicenter Italian study","volume":"11","author":"De Feo","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.euo.2025.06.002_b0320","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clgc.2019.10.009","article-title":"Primary radical prostatectomy or ablative radiotherapy as protective factors for patients with mCRPC treated with radium-223 dichloride: an Italian multicenter study","volume":"18","author":"Frantellizzi","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.06.002_b0325","first-page":"12","article-title":"Baseline quality of life predicts overall survival in patients with mCRPC treated with223Ra-dichloride","volume":"23","author":"Frantellizzi","year":"2020","journal-title":"Hellenic J Nucl Med"},{"key":"10.1016\/j.euo.2025.06.002_b0330","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2023.41.6_suppl.96","article-title":"Radium-223 for mCRPC, a real-world experience study from 7 Galician medical centers","volume":"41","author":"Herranz","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0335","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2967\/jnumed.119.231100","article-title":"Assessing radiographic response to 223Ra with an automated bone scan index in metastatic castration-resistant prostate cancer patients","volume":"61","author":"Anand","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2025.06.002_b0340","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MNM.0000000000001325","article-title":"Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway","volume":"42","author":"Jarvis","year":"2021","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.euo.2025.06.002_b0345","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10147-020-01850-3","volume":"26","author":"Uemura","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0350","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.3390\/cancers15102784","article-title":"Assessing therapeutic response to radium-223 with an automated bone scan index among metastatic castration-resistant prostate cancer patients: data from patients in the J-RAP-BSI trial","volume":"15","author":"Kitajima","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.06.002_b0355","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.2023.41.6_suppl.119","article-title":"Patient characteristics and safety of radium-223 dichloride in Taiwan: analysis of real world clinical practice","volume":"41","author":"Pang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.002_b0360","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/pros.24053","article-title":"Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians","volume":"80","author":"Shore","year":"2020","journal-title":"Prostate"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:24:00Z","timestamp":1758079440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001725"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}